HHS to drop 340B rebate pilot after court rulings / Beckers

Ella Jeffries / beckershospitalreview - HHS will drop its 340B rebate model pilot program following two federal court rulings that blocked its implementation. The program, announced in August 2025, was challenged by the American Hospital Association, the Maine Hospital Association and four safe…

Ayisha Sharma / endpoints - Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Bayer Reveals Data That Could Make Stroke Prevention Drug Its Next Blockbuster Product

5 wks / medcitynews / Frank Vinluan

#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial

5 wks / endpoints / Ayisha Sharma

Saturday, February 7, 2026, 3:21 am / permalink 18873 / 2 stories in 5 wks

Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery / OncoDaily

oncodaily - Eikon Therapeutics has raised $381 million through its IPO, pricing at the top of its range in a strong sign of renewed investor appetite for biotech offerings. The South San […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery

5 wks / oncodaily

Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials

5 wks / medcitynews / Frank Vinluan

Saturday, February 7, 2026, 1:21 am / permalink 18871 / 2 stories in 5 wks

HHS scraps 340B rebate pilot in win for hospitals / Healthcare Dive

Emily Olsen / healthcaredive - The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates on some drugs instead of upfront discounts.

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy

Senate Questions Health Care Firm for Profiting Off Program Meant for Poor

4 wks / nytimes / Ellen Gabler

AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight

4 wks / endpoints / Nicole DeFeudis

Court upholds Louisiana’s 340B discount law

4 wks / beckershospitalreview / Ella Jeffries

HHS drops legal fight over blocked 340B rebate pilot

5 wks / endpoints / Nicole DeFeudis

HHS scraps 340B rebate pilot in win for hospitals

5 wks / healthcaredive / Emily Olsen

Saturday, February 7, 2026, 12:23 am / permalink 18867 / 5 stories in 5 wks

Statin pills much safer than advertised, major review finds / BBC

bbc - The results, in The Lancet journal, come from trials involving more than 120,000 people comparing statins with a dummy drug or placebo.

#healthcare #pharmaceuticals #publichealth

Statin pills much safer than advertised, major review finds

5 wks / bbc

Statins don't cause most of the side effects listed on their labels

5 wks / newscientist

Statins do not cause the majority of side effects listed in package leaflets, large-scale analysis finds

5 wks / medicalxpress

Thursday, February 5, 2026, 8:24 pm / permalink 18820 / 3 stories in 5 wks

Novo Nordisk vows legal action to protect Wegovy pill / Medical Express

medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.

#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #drugdevelopment #digitalhealth

Novo Nordisk to expand Irish factory for Wegovy pill

4 wks / endpoints / Anna Brown

Blockbuster weight loss drugs like Ozempic deliver big results but face big questions

4 wks / sciencedaily

Why people won't quit a weight loss drug, even when it makes them feel sick

4 wks / medicalxpress

FDA to Novo Nordisk: Correct ‘misleading’ GLP-1 pill TV ad

4 wks / beckershospitalreview / Erica Cerutti

The fallout from Novo vs. Hims

4 wks / endpoints / Lydia Ramsey Pflanzer

Hims pulls cheaper Wegovy pill after federal scrutiny

5 wks / medicalxpress

Hims retreats from weight loss pill launch as Novo, FDA pressure mounts

5 wks / fiercehealthcare

After industry pressure, Hims & Hers stops selling Wegovy pill

5 wks / beckershospitalreview / Paige Twenter

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

5 wks / endpoints / Elizabeth Cairns

'Weight-loss jab helped me find my cancer'

5 wks / bbc

Hims & Hers Withdraws Knockoff Weight-Loss Pill After Regulatory Scrutiny

5 wks / nytimes / Rebecca Robbins

Hims says it will stop selling GLP-1 pill, after legal pressure from US

5 wks / endpoints / Drew Armstrong

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

5 wks / endpoints / Max Gelman

US calls for DOJ investigation of Hims over GLP-1 drugs

5 wks / endpoints / Shelby Livingston

Synergizing global clinical trials data: GLP-1 receptor agonist safety and novel clinical applications

5 wks / medicalxpress

FDA's Makary pledges crackdown on mass marketing of 'illegal copycat drugs' in wake of Hims' Wegovy pill push

5 wks / fiercehealthcare

FDA chief Makary takes aim at Hims' compounded Wegovy pill plans

5 wks / endpoints / Max Bayer

Novo's threat to sue Hims over Wegovy pill faces legal hurdle

5 wks / endpoints / Shelby Livingston

War breaks out over GLP-1 pills

5 wks / beckershospitalreview / Paige Twenter

Novo Nordisk vows legal action to protect Wegovy pill

5 wks / medicalxpress

Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action

5 wks / fiercehealthcare

Telehealth provider Hims goes after Novo's weight-loss pill with compounded version

5 wks / endpoints / Zachary Brennan

Thursday, February 5, 2026, 3:23 pm / permalink 18807 / 22 stories in 5 wks

FTC deal over insulin prices forces Express Scripts to overhaul policies / Beckers

Elizabeth Casolo / beckershospitalreview - The Federal Trade Commission reached a settlement with Cigna’s Express Scripts in a case over alleged inflation of insulin prices, according to a Feb. 4 agency news release. Under the settlement, Express Scripts must keep drug manufacturer compensation de…

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy

Employers Celebrated PBM Reform. The Reality Is More Complicated

5 wks / medcitynews / Marissa Plescia

Employers, pharmacists cheer as Congress finally passes PBM reform

5 wks / fiercehealthcare

‘Meh’: Mark Cuban casts doubt on FTC, Cigna’s Express Scripts settlement

5 wks / beckershospitalreview / Elizabeth Casolo

FTC deal over insulin prices forces Express Scripts to overhaul policies

5 wks / beckershospitalreview / Elizabeth Casolo

FTC settles insulin lawsuit with Express Scripts

5 wks / endpoints / Max Bayer

F.T.C. Settles With Express Scripts Over High Insulin Prices

5 wks / nytimes / Rebecca Robbins and Reed Abelson

Wednesday, February 4, 2026, 3:25 pm / permalink 18768 / 6 stories in 5 wks

Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade / Calgary Sun

Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

STS: Assessment of more than one nodal station tied to increased upstaging, survival in NSCLC

5 wks / medicalxpress

Jad Chahoud: Why Timing of Immunochemotherapy Matters in Lung Cancer

5 wks / oncodaily

Giannis Mountzios: What happens to patients with st3 unresectable NSCLC who never receive maintenance IO?

5 wks / oncodaily

Cordyceps sinensis enhances the efficacy of anti-PD-1 immunotherapy in Lewis lung adenocarcinoma

5 wks / nature

Therapeutic potential of targeting MASTL in lung adenocarcinoma

6 wks / nature

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

6 wks / nature

Narjust Florez: Global Advances and Strategic Priorities in Lung Cancer Care

6 wks / oncodaily

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutated NSCLC After TKI Therapy

6 wks / oncodaily

Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade

6 wks / calgarysun / Jeffrey Morgan

Saturday, January 31, 2026, 2:22 pm / permalink 18622 / 9 stories in 6 wks

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia / Endpoints

Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

Gene-editing therapy proves effective for Leber's hereditary optic neuropathy

5 wks / medicalxpress

China startup AccurEdit raises $75M for gene editing therapies

5 wks / endpoints / Ryan Cross

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

6 wks / endpoints / Lei Lei Wu

FDA lifts hold on Intellia’s phase 3 trial for genetic nerve disease

6 wks / beckershospitalreview / Ella Jeffries

Saturday, January 31, 2026, 7:22 am / permalink 18610 / 4 stories in 6 wks

‘Vertical integration is destroying people’s ability to access care’: Payer CEOs face bipartisan congressional grilling / Beckers

Jakob Emerson / beckershospitalreview - The CEOs of the nation’s largest health insurers drew the ire of lawmakers on both sides of the aisle during congressional hearings Jan. 22 over industry consolidation, prior authorization practices and executive pay, with members pressing executives to e…

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #mergersandacquisitions #corporatetakeover

Congress Reins In Drug Middlemen in Effort to Lower Prescription Prices

5 wks / nytimes / Reed Abelson and Rebecca Robbins

When Health Insurance Costs More Than the Mortgage

6 wks / kffhealthnews / Renuka Rayasam

Is It Time to Change the Independent Dispute Resolution Process of the No Surprises Act?

6 wks / medcitynews / Marissa Plescia

Medication Affordability Depends on Total Price Transparency

6 wks / medcitynews / Miriam Paramore

Labor Department proposes PBM compensation disclosure rule for self-insured plans

6 wks / beckershospitalreview / Elizabeth Casolo

Could a unified AI platform relieve payer-provider tensions?

6 wks / beckershospitalreview / Elizabeth Casolo

Sick of fighting insurers, hospitals offer their own Medicare Advantage plans

6 wks / medicalxpress

Lack of regulation of short-term insurance plans cuts timely cancer treatment

6 wks / medicalxpress

KFF: Nearly 53M prior auth requests submitted in Medicare Advantage in 2024

6 wks / fiercehealthcare

A bad week for health insurers

6 wks / beckershospitalreview / Jakob Emerson

Providence CEO calls for Medicare Advantage ‘reset’ amid wave of network exits

6 wks / beckershospitalreview / Alan Condon

Watch: A Strange Checkup Bill Revealed a Firefighter’s Kids Were Mistakenly Uninsured

6 wks / kffhealthnews / Caresse Jackman, InvestigateTV

The case for transparent pricing: Making pharmacy benefits work for health plans

7 wks / healthcaredive / CVS Caremark

Is your billing system costing you too much?

7 wks / healthcaredive

Sick of Fighting Insurers, Hospitals Offer Their Own Medicare Advantage Plans

7 wks / kffhealthnews / Susan Jaffe

AHA outlines concerns with hospital price transparency proposals

7 wks / beckershospitalreview / Andrew Cass

‘Act like a payer’: A CFO’s strategy for margin growth

7 wks / beckershospitalreview / Laura Dyrda

Washington state lawmakers consider banning interest on medical debt

7 wks / beckershospitalreview / Andrew Cass

Healthcare’s Paper Check Problem

7 wks / medcitynews / Tom Davis

Insurance CEOs’ no good, very bad day on the Hill

7 wks / healthcaredive / Rebecca Pifer Parduhn

Express Scripts considering settlement in FTC insulin price lawsuit

7 wks / healthcaredive / Emily Olsen

Health Plan Transformation: HR Exec Shares How and Why an Employer Changed Its Approach to Healthcare

7 wks / medcitynews / Stephanie Baum

Insurance CEOs defend their businesses at House hearing

7 wks / endpoints / Shelby Livingston

Lawmakers Grill Health Insurance CEOs: 4 Key Takeaways

7 wks / medcitynews / Marissa Plescia

Big Insurers Try to Shift Blame for High Health Costs to Hospitals and Drug Makers

7 wks / nytimes / Reed Abelson

‘Vertical integration is destroying people’s ability to access care’: Payer CEOs face bipartisan congressional grilling

7 wks / beckershospitalreview / Jakob Emerson

Small business health insurance coverage at risk as costs rise, EBRI finds

7 wks / healthcaredive / Ginger Christ

Thursday, January 22, 2026, 9:22 pm / permalink 18314 / 27 stories in 7 wks

#JPM26: Day 3 at the JP Morgan Healthcare Conference / Endpoints

ENDPOINTS / endpoints - It’s Wednesday at the JP Morgan Healthcare Conference, and as the sessions wind down, we’ll be keeping an eye on presentations from WuXi AppTec and AbbVie. Yesterday afternoon, our Executive Editor Drew Armstrong spoke with ...

#obesity #healthcare #pharmaceuticals #weightloss #biotech #drugdevelopment #digitalhealth

What if Oprah Knew About Fractyl Health?

6 wks / medcitynews / Arundhati Parmar

Which Digital Health Startups Will Win in 2026?

6 wks / medcitynews / Katie Adams

CMS picks Lilly’s Trulicity for third round of Medicare negotiations

6 wks / endpoints / Nicole DeFeudis

The future GLP-1 might be a gene therapy: Report

7 wks / beckershospitalreview / Paige Twenter

Vivek Subbiah: AI-Driven Screening Opens New Era in Drug Discovery

7 wks / oncodaily

David K. Lee: What’s Ahead for Servier in 2026 – Strengthening Our Pipeline, Expanding Our Impact

7 wks / oncodaily

Industry Voices—Micro-app strategy can lead to macro improvements

7 wks / fiercehealthcare

Five Collaboration Trends That Shaped Healthcare AI in 2025

7 wks / medcitynews / Marva Bailer

How Bessemer Sees 2026 Shaping Up as Healthcare AI’s Breakout Year

7 wks / medcitynews / Katie Adams

#JPM26: Hua Medicine plots diabetes drug expansion in China and beyond

7 wks / endpoints / Jared Whitlock

Viewpoint: What Taylor Swift and JPM2026 can teach us about the ‘next era’ of healthcare

7 wks / beckershospitalreview / Mackenzie Bean

Walid Kamoun: Closing J.P. Morgan with Our AI Partnership Expedition

7 wks / oncodaily

Bristol Myers Squibb, Microsoft partner on AI lung cancer detection

7 wks / beckershospitalreview / Ella Jeffries

Bristol Myers Squibb Announces Collaboration with Microsoft to Accelerate the Early Detection of Lung Cancer

7 wks / oncodaily

#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets

7 wks / endpoints / Andrew Dunn

J&J, Isomorphic sign research deal for AI-made molecules

7 wks / endpoints / Andrew Dunn

GSK makes $2.2B deal for RAPT and its food allergy candidate

7 wks / endpoints / Kyle LaHucik

JPM Deals Recap: Boston Scientific Acquisition, a Mega Round for Parabalis, Enodia Emerges & More

1 month / medcitynews / Frank Vinluan

10 Key MedTech Themes for 2026

1 month / medcitynews / Vinita Kailasanath, Kayla Weston, Yungjee Kim and Shannon O’Hara

Bill Gates: AI Innovations Must Reach the People Who Need Them Most

1 month / oncodaily

Zhaohui Su: Federated Learning With Differential Privacy Balances Accuracy and Patient Data Protection

1 month / oncodaily

Zhaohui Su: AI, Decentralization, and the Evolution of Clinical Trials

1 month / oncodaily

Proud to Have Renee Gala Represent at the 44th J.P. Morgan Healthcare Conference – Jazz Pharmaceuticals

1 month / oncodaily

Zhen Su: Unlocking the Full Potential of Invika as a Next-Generation Immuno-Oncology Backbone

1 month / oncodaily

#JPM26: Day 3 at the JP Morgan Healthcare Conference

2 months / endpoints / ENDPOINTS

#JPM26: Q&A with Bristol Myers Squibb CEO Chris Boerner on 2026 outlook

2 months / endpoints / Andrew Dunn

#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom

2 months / endpoints / Ngai Yeung

JPM26: Elation Health embeds Anthropic's Claude into EHR to power chart summaries

2 months / fiercehealthcare

Saturday, January 17, 2026, 7:21 pm / permalink 18138 / 28 stories in 1 month

F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds / NYT

Pam Belluck / nytimes - A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda

Why medication abortion is the top target for anti-abortion groups in 2026

6 wks / medicalxpress

FDA asks court to pause Louisiana's abortion pill fight

6 wks / endpoints / Max Bayer

Why Medication Abortion Is the Top Target for Anti-Abortion Groups in 2026

7 wks / kffhealthnews / Julie Rovner, KFF Health News

Study finds FDA used evidence, not politics, in abortion pill decisions

2 months / medicalxpress

F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds

2 months / nytimes / Pam Belluck

Saturday, January 17, 2026, 8:21 am / permalink 18126 / 5 stories in 1 month

#JPM26: Day 1 at the JP Morgan Healthcare Conference / Endpoints

ENDPOINTS / endpoints - It’s day 1 at the JP Morgan Healthcare Conference, and the mood heading into the week is one of cautious optimism. Biotech fundraising was off to a hot start in 2026. There ...

#healthcare #pharmaceuticals #biotech #digitalhealth

Nvidia CEO to Lilly CEO: You were running around the forest …

7 wks / medcitynews / Arundhati Parmar

R1 RCM launches prior authorization tool

7 wks / beckershospitalreview / Andrew Cass

AI in Radiotherapy Planning and Workflow Optimization 2026

7 wks / oncodaily

Marty Makary: FDA Priorities for 2026 at JPM26

1 month / oncodaily

JPM26: CommonSpirit CEO teases new divestures, outlines AI wins and pitfalls

2 months / fiercehealthcare

JPM26, Day 1: Waystar rolls out agentic AI; Tempus notches partnerships with Northwestern Medicine, NYU Langone

2 months / fiercehealthcare / , ,

#JPM26: Day 1 at the JP Morgan Healthcare Conference

2 months / endpoints / ENDPOINTS

JPM26: Abridge teams up with Availity to scale real-time prior authorization

2 months / fiercehealthcare

Interpretable inflammation landscape of circulating immune cells

2 months / nature / Laura Jiménez-Gracia

Saturday, January 17, 2026, 8:21 am / permalink 18125 / 9 stories in 1 month

No Link Between Acetaminophen in Pregnancy and Autism, a New Study Finds / NYT

Azeen Ghorayshi / nytimes - The review looked at more than three dozen studies and found no evidence that acetaminophen increased the risk of neurodevelopmental disorders in children.

#healthcare #pharmaceuticals #publichealth #autism #infanthealth

New analysis shows no link between autism and paracetamol

6 wks / nature / Karen O’Leary

No Link Between Acetaminophen in Pregnancy and Autism, a New Study Finds

2 months / nytimes / Azeen Ghorayshi

Taking acetaminophen during pregnancy does not increase risk of autism, ADHD or intellectual disabilities

2 months / medicalxpress

Friday, January 16, 2026, 6:23 pm / permalink 18099 / 3 stories in 2 months

Life-extending prostate cancer drug to be offered to thousands in England / BBC

bbc - Abiraterone will be available in a matter of weeks and will be offered to 7,000 men a year.

#healthcare #pharmaceuticals #publichealth #governmentpolicy

Novel laser therapy device generates promising results in prostate cancer clinical trial

6 wks / medicalxpress

Guru Sonpavde: Updates and Practice-Changing Highlights in Bladder, Prostate, and Kidney Cancer at ASCO GU2026

7 wks / oncodaily

Adam Weiner: SGLT2 inhibitors and ADT failure for Patients with Prostate Cancer

7 wks / oncodaily

Aruni Ghose Presents Powerful Considerations Shaping Optimal mCRPC Treatment Sequencing

7 wks / oncodaily

Michelle Mitchell: How Sustained Investment in Research Leads to Meaningful Impact

1 month / oncodaily

Alliance Trial Reveals Gene Variant May Affect Prostate Cancer Drug Efficacy

1 month / oncodaily

Prognostic impact of spatial niches in prostate cancer

2 months / nature

Thousands more men in England offered abiraterone, one of our prostate cancer treatment breakthroughs

2 months / cancerresearchuk / Tim Gunn

Life-extending prostate cancer drug to be offered to thousands in England

2 months / bbc

Friday, January 16, 2026, 2:22 pm / permalink 18069 / 9 stories in 2 months

FDA rejects cancer therapy for rare post-transplant disease / Beckers

Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

FDA rejects cancer therapy for rare post-transplant disease

2 months / beckershospitalreview / Ella Jeffries

FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus

2 months / endpoints / Max Gelman

Friday, January 16, 2026, 11:55 am / permalink 18057 / 2 stories in 2 months

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access / Beckers

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #biotech

Stephen Liu: What GLP-1 Therapies May Mean for Cancer Risk

7 wks / oncodaily

#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026

2 months / endpoints / Andrew Dunn

A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit

2 months / endpoints / Shelby Livingston

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

2 months / beckershospitalreview / Ella Jeffries

Thursday, January 15, 2026, 1:23 pm / permalink 17926 / 4 stories in 2 months

NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily

oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]

#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment

NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery

2 months / oncodaily

Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratory

2 months / endpoints / Andrew Dunn

Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 2 months

FDA moves to remove suicide warnings from GLP-1 weight loss drugs / Medical Express

medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #governmentpolicy #fda

Physician-Journalist Shines Light on Measles Upsurge and New GLP-1 Study

1 month / kffhealthnews

What Merck’s Chief Medical Officer Thinks of Lilly’s Approach to GLP-1s

2 months / medcitynews / Arundhati Parmar

Long-term GLP-1 use trims medical cost growth: Aon

2 months / beckershospitalreview / Elizabeth Casolo

GLP-1s tied to improved survival in colorectal cancer

2 months / beckershospitalreview / Paige Twenter

FDA moves to remove suicide warnings from GLP-1 weight loss drugs

2 months / medicalxpress

Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial

2 months / nature / Atul Malhotra

FDA moves to strike suicide risk warnings from 3 GLP-1s

2 months / beckershospitalreview / Ella Jeffries

FDA asks Lilly, Novo to remove suicide warnings from GLP-1 labels

2 months / endpoints / Zachary Brennan

Thursday, January 15, 2026, 1:23 pm / permalink 17924 / 8 stories in 2 months

Merck Could Strike 30 Billion Deal for Revolution Medicines / OncoDaily

oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]

#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Merck Could Strike 30 Billion Deal for Revolution Medicines

2 months / oncodaily

Speculation builds about a deal for Revolution Medicines

2 months / endpoints / Kyle LaHucik

Monday, January 12, 2026, 1:21 am / permalink 17767 / 2 stories in 2 months

Tag Directory / PHARMACEUTICALS showing 61–80 of 120

HHS to drop 340B rebate pilot after court rulings / Beckers

#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial / Endpoints

Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery / OncoDaily

HHS scraps 340B rebate pilot in win for hospitals / Healthcare Dive

Statin pills much safer than advertised, major review finds / BBC

Novo Nordisk vows legal action to protect Wegovy pill / Medical Express

FTC deal over insulin prices forces Express Scripts to overhaul policies / Beckers

Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade / Calgary Sun

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia / Endpoints

‘Vertical integration is destroying people’s ability to access care’: Payer CEOs face bipartisan congressional grilling / Beckers

#JPM26: Day 3 at the JP Morgan Healthcare Conference / Endpoints

F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds / NYT

#JPM26: Day 1 at the JP Morgan Healthcare Conference / Endpoints

No Link Between Acetaminophen in Pregnancy and Autism, a New Study Finds / NYT

Life-extending prostate cancer drug to be offered to thousands in England / BBC

FDA rejects cancer therapy for rare post-transplant disease / Beckers

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access / Beckers

NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily

FDA moves to remove suicide warnings from GLP-1 weight loss drugs / Medical Express

Merck Could Strike 30 Billion Deal for Revolution Medicines / OncoDaily

PHARMACEUTICALS Heatmap

More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

CMS proposes sweeping changes to ACA marketplace plan rules

Tenet forecasts major ACA exchange enrollment drop and financial hit

City of Hope promotes Nisha Morris to senior marketing chief